List view / Grid view

David Lonard (CoRegen)

 

article

SRC-3: CoRegen’s revolutionary approach to cancer

Drug Target Review’s Taylor Mixides exclusively interviews David Lonard, PhD,…

6 October 2023 | By

Drug Target Review’s Taylor Mixides exclusively interviews David Lonard, PhD, Chief Scientific Officer at CoRegen and Associate Professor at Baylor University, to uncover the mechanisms of SRC-3 and why it’s key to targeting cancer – and only cancer.